61
Participants
Start Date
July 31, 2013
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Albuterol Spiromax
Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
ProAir HFA
ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
Placebo
Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Teva Investigational Site 10598, Birmingham
Teva Investigational Site 10593, Little Rock
Teva Investigational Site 10610, Costa Mesa
Teva Investigational Site 10582, Huntington Beach
Teva Investigational Site 10606, Orange
Teva Investigational Site 10597, San Jose
Teva Investigational Site 10596, Jacksonville
Teva Investigational Site 10599, Lawrenceville
Teva Investigational Site 10580, Savannah
Teva Investigational Site 10592, Normal
Teva Investigational Site 10602, Missoula
Teva Investigational Site 10578, Raleigh
Teva Investigational Site 10577, Oklahoma City
Teva Investigational Site 10589, Medford
Teva Investigational Site 10604, Portland
Teva Investigational Site 10591, Charleston
Teva Investigational Site 10609, Orangeburg
Teva Investigational Site 10579, Spartanburg
Teva Investigational Site 10588, Boerne
Teva Investigational Site 10605, New Braunfels
Teva Investigational Site 10583, San Antonio
Teva Investigational Site 10576, Waco
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY